Tafluprost for glaucoma

Expert Opin Pharmacother. 2011 Oct;12(15):2393-401. doi: 10.1517/14656566.2011.606810.


Introduction: Lowering intraocular pressure (IOP) is, at present, the only therapeutic approach to the treatment of glaucoma. Good compliance is essential in every chronic therapy; therefore, the development of IOP-lowering eye drops that are well tolerated and have an easy administration schedule is essential for the treatment of glaucoma. Prostaglandins are a first-choice drug class for the treatment of glaucoma.

Areas covered: This review provides a background on tafluprost, a newly synthesized prostaglandin analogue, and summarizes the existing data on its efficacy and safety, including comparative data with the other prostaglandin derivatives now available on the market. A review of the literature was performed.

Expert opinion: Current research focuses not only on the efficacy of the drugs but also on their tolerability. The importance of obtaining good compliance by the patient is increasingly relevant; therefore, new formulations are studied to provide fewer side effects and an easier schedule. Tafluprost is a new prostaglandin analogue that has been marketed in some European countries and in Japan for more than 2 years and was recently (July 2009) approved in 21 countries. Besides a well-demonstrated IOP-lowering effect, tafluprost is the first topical prostaglandin available as a preservative-free formulation.

Publication types

  • Review

MeSH terms

  • Administration, Ophthalmic
  • Glaucoma / drug therapy*
  • Glaucoma / physiopathology
  • Glaucoma / surgery
  • Humans
  • Hypersensitivity / etiology
  • Intraocular Pressure
  • Prostaglandins F / administration & dosage
  • Prostaglandins F / adverse effects
  • Prostaglandins F / therapeutic use*


  • Prostaglandins F
  • tafluprost